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ABSTRACT 
Objective: This study estimated the cost-effectiveness, 
from the Dutch health care perspective, of screening 
for albuminuria in the general Dutch population to 
prevent cardiovascular events (CVEs) with subsequent 
angiotensin-converting e zyme inhibitor treatment, us- 
ing data from the Prevention of REnal and Vascular 
ENdstage Disease Intervention Trial (PREVEND IT). 
Methods: PREVEND IT was a single-center, double- 
blind, randomized, placebo-controlled trial with a 
2 × 2 factorial design within the larger observational 
Prevention of REnal and Vascular ENdstage Disease 
(PREVEND) study. The PREVEND IT study was con- 
ducted to assess the effects of fosinopril 20 mg and 
pravastatin 40 mg on CVEs in subjects with specific 
inclusion criteria: urinary albumin excretion (UAE) 
rate in the range from 15 to 300 mg/d, blood pres- 
sure <160/100 mm Hg, and plasma cholesterol level 
<8.0 mmol/L. Cost-effectiveness e timates for the 
Dutch population were expressed in euros (2002; 1£ = 
US $1.01) as net costs per life-year gained (LYG) in 
the baseline and sensitivity (stochastic) analyses. 
Results: Data were assessed for 864 subjects, with 
a mean (SD) follow-up of 46 (7) months. CVEs oc- 
curred in 45 (5.2%) subjects. Subjects who received 
fosinopril had a 40% lower incidence of CVEs than 
subjects in the placebo group (3.9% vs 6.5%, respec- 
tively; P -- NS). The cost-effectiveness of creening for 
albuminuria was determined to be (~16,700/LYG for 
the study population. Stochastic analysis indicated 
that the probability of the cost-effectiveness being be- 
low the suggested Dutch threshold of (~20,000/LYG 
was 59% in the baseline analysis. The probability of 
cost-effectiveness below C20,000/LYG would increase 
to 91% if only subjects with UAE >50 mg/d were 
treated with fosinopril. Limiting the screening to sub- 
jects aged >50 years and >60 years also improved 
cost-effectiveness. 
Conclusions: The results of our study suggest that 
screening the general Dutch population for albumin- 
uria and subsequently treating those found positive 
with fosinopril may be cost-effective compared with 
no screening and adopting the Dutch health care per- 
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spective. However, confirmation from larger multi- 
center trials is needed. (Clin Ther. 2006;28:432-444) 
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INTRODUCTION 
Cardiovascular disease (CVD) is one of the leading 
causes of death in many countries. 1,2 In The Nether- 
lands, CVD accounts for -11% of all health care 
costs. 3Microalbuminuria, defined as a slightly elevat- 
ed albumin level (urinary albumin excretion [UAE] 
>30 and <300 mg/d), is a marker associated with an 
increased risk for cardiovascular (CV) morbidity and 
mortality in subjects with diabetes 4,s or hypertension, 6 
and in the general population. 7-9 Screening for mi- 
croalbuminuria, either alone or in combination with 
screening for hypertension and hypercholesterolemia, 
may be a useful tool to identify subjects at risk for 
CVD and/or progressive renal failure. 1° Use of anti- 
hypertensive agents has been shown to be effective 
in reducing the incidence of cardiovascular events 
(CVEs)) 1 Antihypertensive interventions, particularly 
with angiotensin-converting e zyme (ACE) inhibitors, 
have been reported to lower UAE in subjects with or 
without diabetes, and in those with essential hyperten- 
sion. 11,12 However, it is not known whether an inter- 
vention focusing specifically on the reduction of UAE 
will result in a decrease in CVEs. Therefore, the Pre- 
vention of REnal and Vascular ENdstage Disease 
Intervention Trial (PREVEND IT) 13 was designed to 
assess the effects of an ACE inhibitor on the incidence 
of CVEs in subjects with elevated UAE. 
Various trials have reported the benefits of CVD 
prevention. In studies reporting the cost-effectiveness 
of secondary prevention, 14-18 most have found favor- 
able cost-effectiveness for the use of ACE inhibitors in 
preventing CVEs in high-risk subjects. However, there 
have been few investigations of their cost-effectiveness 
in primary prevention, particularly with respect o 
nephrology markers.19, 2°Prevention based on albumin- 
uria measurement i  the general community may be an 
option for primary prevention. Golan et a121 reported 
that treatment with ACE inhibitors in subjects with 
macroalbuminuria (UAE >300 mg/d) and diabetic 
nephropathy was cost-effective in preventing end-stage 
renal disease. Palmer et a122 found that the use of 
angiotensin-receptor antagonists in subjects with dia- 
betes was more cost-effective, when compared with other 
antihypertensives used to improve life expectancy, if 
treatment was started uring the early microalbuminuria 
stage (ie, UAE >30 mg/d). However, Boulware et a123 
found that screening the general population for albu- 
minutia was not cost-effective when considering renal out- 
comes (end-stage renal disease). As of the time of writ- 
ing, no cost-effectiveness study has been directed at the 
prevention of CVEs (PubMed; up to 2005; key terms: 
cost-effectiveness, albuminuria, cardiovascular disease). 
Therefore, the present study aimed to investigate the 
cost-effectiveness of screening for albuminuria to pre- 
vent CVEs with ACE-inhibitor treatment using data 
from the Prevention of REnal and Vascular ENdstage 
Disease (PREVEND) and PREVEND IT. 8,13,24,25 
PREVEND IT compared the effect of the ACE in- 
hibitor fosinopril and the 3-hydroxy-3-methylglutaryl- 
coenzyme A-reductase inhibitor pravastatin on the 
incidence of CVEs in subjects with albuminuria 
(>15 rag/d) and normal blood pressure and serum 
cholesterol levels. 13 During a 4-year treatment period, 
fosinopril was associated with a significant reduction 
in albuminuria compared with placebo (20.9% de- 
crease vs 4.7% increase, respectively; P < 0.001) and 
numerically fewer CVEs (P = NS). The fosinopril group 
had a 40% lower incidence of CVEs compared with 
the placebo group (number needed to treat [NNT], 
38). Subjects with microalbuminuria (>50 mg/d) had 
a 60% lower incidence of CVEs than those in the 
placebo group (NNT, 13). Pravastatin treatment was 
not associated with a significant reduction in albumin- 
uria or a significant change in the incidence of CVEs 
(4.8% decrease related to pravastatin vs 5.6% in 
placebo; hazard ratio, 0.87 [95% CI, 0.49-1.57]). Be- 
cause the present analysis was based on the nonsig- 
nificant trend toward fewer CVEs with fosinopril in 
PREVEND IT, it should be interpreted as a hypothesis- 
generating study whose findings need confirmation in 
larger multicenter t ials. 
SUBJECTS AND METHODS 
PREVEND and PREVEND IT 
The design and principal results of the PREVEND 
IT 13 and the PREVEND study have been reported in 
detail elsewhere. PREVEND IT is part of the ongo- 
ing PREVEND study,8, 24 and subjects for PREVEND 
IT were recruited from the PREVEND cohort. The 
PREVEND study was designed to study the impact of 
albuminuria levels on CV and renal morbidity and 
mortality in the general Dutch population. In 1997- 
1998, the prescreening phase began when all inhabi- 
tants aged 28 to 75 years in the city of Groningen (N = 
85,421) were invited to send in a morning urine sam- 
ple for measurement of the urinary albumin concen- 
tration (UAC) and to complete a questionnaire on 
demographic characteristics and CV history (Figure 1). 
Responses were received from 40,856 persons. Based 
on their UAC, subjects were invited for further study. 
Of the 40,856 responders, 9966 had a UAC _>10 mg/L. 
Excluded from further study were diabetic subjects 
(n = 167), pregnant women (n = 60), and those who 
declined to participate (n = 3739). Two urine samples 
were collected in a 24-hour period from each of the 
remaining 6000 subjects. These subjects were invited 
to the outpatient clinic for testing and further assess- 
ment of CV risk factors and CV and renal morbidity. 
At this stage, subjects with erythrocyturia or leukocy- 
turia, known renal disease, or missing data were ex- 
cluded. Of the final group of subjects, 3964 had 
normal UAE (<15 mg/d); 1105 had high-normal UAE 
(15-30 mg/d); 931 had microalbuminuria (UAE 
30-300 mg/d), including 498 with high microalbu- 
minuria (UAE 50-300 mg/d); and 82 had macro- 
albuminuria (UAE >300 mg/d). 26 
Formal inclusion criteria for the PREVEND IT study 
were persistent albuminuria (1 UAC measurement 
>10 mg/L and _>1 UAE measurement of 15-300 rag/d), 
blood pressure <160/100 mm Hg (threshold for nor- 
mal blood pressure according to Dutch guidelines at 
the time of the design of the study2;), no use of anti- 
hypertensive or lipid-lowering drugs, and total plasma 
cholesterol <8.0 mmol/L (<5.0 mmol/L in the case of 
previous myocardial infarction). 
Eight hundred sixty-four subjects who fulfilled the 
inclusion criteria were willing to participate in the 
study. These subjects were randomized to receive fo- 
sinopril 20 mg, fosinopril placebo, pravastatin 40 mg, 
or pravastatin placebo in a 2 × 2 factorial design. 13 
The primary end point of PREVEND IT was the in- 
cidence of CVEs, defined as CV mortality, nonfatal 
myocardial infarction or myocardial ischemia, heart 
failure, peripheral vascular disease, or cerebrovascular 
attack. 
The CVE rate in the PREVEND IT population was 
-15%. The planned sample size of 450 subjects in each 
arm (450 fosinopril vs 450 placebo or 450 pravastat- 
in vs 450 placebo, based on the 2 × 2 factorial de- 
sign) provided a power of -80% to detect a significant 
difference in the incidence of CVEs between the active- 
treatment and placebo arms. 13 
Subjects included in PREVEND IT had a mean (SD) 
age of 51 (2) years, and 65% were male. They had rela- 
tively normal systolic and diastolic blood pressure 
(130 [18]/76 [10] mm Hg) and cholesterol levels (5.8 
[1.0] mmol/L). Median UAE was 22.8 (15.8-41.3) mg/d. 
During follow-up (46 [7] months), the primary end 
point occurred in 45 (5.2%) subjects, 17 (3.9%) in the 
fosinopril group (n = 431) and 28 (6.5%) in the pla- 
cebo group (n = 433) (hazard ratio, 0.60; 95% CI, 
0.33-1.10; P = 0.098, log-rank test). Because of the 
2 × 2 factorial design, patients in both the fosinopril 
and placebo groups also may have received pravastat- 
in (Figure 1, Table I). In post hoc analysis, this effect 
differed in subjects with a UAE >50 mg/d who re- 
ceived fosinopril, whereby a relative risk reduction in 
CVEs of up to 60% was observed (5.2% vs 13.0%; 
P = NS). Also, a significantly worse prognosis for event- 
free survival was associated with a UAE >50 mg/d in 
subjects receiving placebo (P = 0.008). The primary 
end point occurred in 21 (4.8%) subjects in the prava- 
statin group (n = 433) and 24 (5.6%) subjects in the 
placebo group (n = 431) (hazard ratio, 0.87; 95% CI, 
0.49-1.57; P = NS) .  13 
Study Design 
The present study was a cost-effectiveness analysis 
with a focus on net costs per life-year gained (LYG). 28,29 
In all calculations, fosinopril treatment was assumed 
after detection of a UAE above the defined thresh- 
old. In the baseline analysis, this threshold was set at 
15 mg/d. For efficacy, subjects receiving fosinopril 
(n = 431) were compared with subjects receiving place- 
bo (n = 433), regardless of the receipt of pravastatin 
treatment in the 2 × 2 factorial design. This approach 
optimized the number of subjects included in the 
economic analysis. In the sensitivity analysis, cost- 
effectiveness was analyzed based on age (>50 and 
>60 years13), and the cutoff for albuminuria was var- 
ied (>30 and >50 rag/d). 
The study adopted the Dutch health care perspec- 
tive and focused on the costs of hospital resource use 
for CVEs: hospitalizations, diagnostic tests, and thera- 
peutic procedures. Additionally, the estimated costs of 
screening and fosinopril treatment were included. 
Patient-level data on resource use were collected over 
the full period of study follow-up. All costs were ex- 











Invited to participate [ 
(N : 85,421) E 
Responded via morning spot urine sample -/~ 
(n = 40,856) ~i 
J 
UAC >10 mg/L i 
(n = 9966) I 
Clinical measurements, wo ~ 
24-hour urine collections ~ 
(n : 6000) i 
3 
UAE 15-300 mg/d 
(n = 2036) 
I - - - - -  "" " ' - - - -  -' - (Normalblood-pressure and cholesterol level 
(n = 1439) 
Gave informed consent o participate in | 
double-blind RCT (2 × 2 factorial design) | 
(n = 864) i 
[ ........................................... I 
L Randomized to treatment I 
! [ ............ I . . . . . .  
Fosinopril + 
pravastatin 
(n = 216) 
T 
V ] 
CVE end point i 




(n = 215) 
CVE end point | 
(n = 9) J 
Pravastatin + 
placebo 
(n = 217) 
CVEend point i 
Subjects with diabetes, pregnant 
women, and subjects who declined 
to participate were excluded 
. . . . .  L~ 
Placebo + 
placebo 
(n = 216) 
CVE end point ! 
Figure 1. Flow chart of  the design and subjects experiencing the primary end point (a cardiovascular event [CVE]) 
o f  PREVEND IT (Prevention of  REnal and Vascular ENdstage Disease Intervention Trial). UAC = urinary 
albumin concentration; UAE = urinary albumin excretion; RCT = randomized clinical trial. 
Table I. Primary end points of the Prevention of 
REnal and Vascular ENdstage Disease 
Intervention Trial. 
Fosinopril Placebo 
Primary End Point (n = 431) (n = 433) 
Cardiovascular death 3 3 
Nonfatal myocardial 
infarction 12 11 
Percutaneus transluminal 
coronary angioplasty 5 4 
Coronary arterial bypass 
grafting 4 2 
Heart failure 0 2 
Peripheral artery disease I 2 
Cerebrovascular disease 
(stroke) 1 10 
Total cardiovascular events 17 28 
Table II. Costs of screening for albuminuria in the 
general Dutch population, based on the 
Prevention of REnal and Vascular ENdstage 
Disease study. 
Cost, 
Screening Stage Year-2002 C 
Prescreening (N = 85,421 ) 282,727 
Screening (n = 6000) 500,909 
Identification of I person with a UAE 
above the specified threshold 
>50 to <300 mg/d (n = 498) 1574 
>30 to <300 mg/d (n = 931) 842 
>15 to <300 mg/d (n = 2036) 385 
UAE = urinary albumin excretion. 
L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Costs 
Screening costs were estimated based on data from 
the PREVEND study (Table II). The costs of inviting 
85,421 persons to take part in the prescreening pro- 
gram and of prescreening 40,856 persons were 
£62,700 for apparatus, £76,800 for administration, 
£61,800 for laboratory materials, and £81,400 for per- 
sonnel. The costs of the subsequent screening program 
were £73,600 for apparatus, £9100 for administration, 
£90,000 for laboratory materials, and ~328,200 for 
personnel. Personnel costs related to research (epidemi- 
ologists and statisticians) were excluded, as these would 
not be part of the routine screening program for which 
cost-effectiveness was estimated. The total costs of the 
prescreening and subsequent screening programs were 
~783,600. The costs of identifying 1person with a UAE 
between 15 and 300 mg/d were estimated at £385. 
Limitation of treatment to those with a UAE of >30 
and >50 mg/d was associated with a higher cost of iden- 
tifying 1 such person (£842 and C1574, respectively). 
The costs of fosinopril were based on actual con- 
sumption during the study follow-up period. The 
costs of general practitioner (GP) visits (~18/visit) and 
pharmacy charges associated with dispensing the pre- 
scription (~6/prescription per 3 months) were also 
taken into account. No visits to the GP were assumed 
for adverse ffects of fosinopril. The costs of medica- 
tion were obtained from the 2002 Dutch Pharmaco- 
therapeutic Guidelines. 3° 
Hospital costs associated with diagnostic and thera- 
peutic procedures for CVEs corresponding to the pri- 
mary end point were derived by multiplying resource 
use by unit costs taken from Dutch tariffs. 31 Daily in- 
patient costs on a regular ward were C199 in a gener- 
al hospital, C279 in an academic hospital, and C889 
for an intensive care unit, based on Dutch reference 
prices for pharmacoeconomic evaluations. 32,33 These 
costs included specialist, resident physician, and nurs- 
ing fees; laundry; nutrition; accommodation a d clean- 
ing; overhead; and equipmentY Costs for outpatient 
visits were ~40 in a general hospital and £70 in an aca- 
demic hospital. 33 Patient-specific costs for medica- 
tions other than the study drugs received uring hos- 
pitalization were not explicitly included (mean costs 
for nonspecific patient medications are incorporated 
into the cost of the inpatient hospital day). Every sub- 
ject with a reported CVE had different otal hospital 
costs, depending on individual diagnostic and thera- 
peutic procedures, length of hospital stay, and number 
of visits to the outpatient clinic. 
Cost-Effectiveness Analysis 
The cost-effectiveness ratio (CER) was expressed in
net costs per LYG. Net costs resulted from the costs of 
screening and fosinopril treatment minus the benefits 
of averted costs related to averted events (ie, screening/ 
treating vs no screening/"doing nothing"). Calcula- 
tion of LYG was based on losses in the remaining 
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life expectancy of subjects with CVEs in both groups 
(fosinopril and placebo). Loss in remaining life ex- 
pectancy after a CVE was estimated using a Dutch 
adaptation of data from the Framingham Study 2 and 
standard Dutch life tables (data for 1998-2002, 
Central Bureau of Statistics). 34 Table [ ]  lists these as- 
sumptions (interpolations were used for ages between 
those presented). Monetary amounts and LYG were 
discounted at 4%, according to Dutch guidelines for 
pharmacoeconomic research. 3~ 
Statistical Analysis 
Bootstrapping of PREVEND IT data (10,000 repli- 
cations) was used to derive 95% CIs for the CER and 
threshold probabilities. 36-39 The bootstrap calcula- 
tion was performed with S-Plus version 7.0 software 
(Insightful Corporation, Seattle, Washington). To de- 
scribe the uncertainty in estimates of the CER, we 
constructed acceptability curves. 4° These curves show 
probabilities that the screen-and-treat in ervention is
acceptable given a specific threshold, above which the 
CER is considered unfavorable and below which it is 
considered favorable. In cost-effectiveness acceptabil- 
ity analyses, we report the median CER and the per- 
centage corresponding to £20,000/LYG, as this figure 
is the only published threshold for The Netherlands 
(no formal threshold exists in The Netherlands for 
cost per quality-adjusted life-year [QALY]). 41 How- 
ever, this threshold is subject o controversy and its 
use should be interpreted with caution. 42,43 
Sensitivity Analysis 
Sensitivity analysis was directed at the performance 
of the intervention in various subgroups and the po- 
tential for targeted implementation. For example, 
analyses were done for the screening of specific age 
groups (in particular, >50 years and >60 years). Ad- 
ditionally, the post hoc analyses were conducted on 
subjects with a UAE >30 mg/d and those with a UAE 
>50 rag/d, using the specific costs of identifying 1 per- 
son with a UAE above these thresholds. Differences in 
the results of the sensitivity and baseline analyses were 
related to the effectiveness of fosinopril in the various 
subgroups and the costs required to identify 1 person 
eligible for fosinopril treatment. 
RES U LTS 
The primary end point in the PREVEND IT trial 
occurred 17 times in the fosinopril group (16 men, 
Table III. Remaining life expectancy at various ages in i 
the general population* and in subjects who i 
have had a cardiovascular event (CVE).~ 
General After a 
Age Population, y CVE, y 
Met1 
SO years 27.8 1,5.9 
60 years 19.3 12.3 
70 years 12.1 8.8 
80 years 6.8 ,5.3 
Women 
,50 years 32.4 20.3 
60 years 23.,5 16.1 
70 years 1.5.4 11.0 
80 years 8.7 7.0 
*Dutch life tables. 34 
~Framingham life tables 2adapted to the Dutch population. 
1 woman) and 28 times in the placebo group (20 men, 
8 women) (Figure 1, Table I). 
Costs 
In the baseline analysis, the costs of CVEs calculated 
from the clinical trial were £207 and ~148 per subject in 
the fosinopril and placebo groups, respectively (Table IV). 
Although fewer events occurred in the fosinopril group, 
per-person costs in that group were higher due to more 
costly treatments per event (more percutaneous translu- 
minal coronary angioplasty and coronary artery bypass 
grafting procedures were performed in this group) 
(Table I). However, differences in the costs of CVEs be- 
tween the 2 groups were not statistically significant. 
The costs of research were excluded from this analysis. 
The calculated costs were applied to the screen- 
and-treat and no-screening strategies (Table IV). Add- 
ing the estimated costs of ~207 for CVEs, ~1296 
for fosinopril treatment (including GP and pharmacist 
costs), and screening costs of £385 (36% for pre- 
screening and 64% screening) resulted in total esti- 
mated costs of £1889 per person (£1809 if discounted). 
No further screening or treatment costs were consid- 
ered for the no-screening option, resulting in a total 
cost of ~148 per person (¢139 if discounted) (Table IV). 
Therefore, the difference in discounted costs between 
the screen-and-treat pproach and the no-screening 
approach was estimated at ~1670 per person. 
Table IV. Estimated mean costs per person for 2 strategies: creening for albuminuria nd treat- 
ing with fosinopril compared with no screening. 
Estimated Mean Costs, Year-2002 £ 
Cost Screen No 
Component and Treat Screening Incremental 
Cardiovascular events 207 148 59 
Procedures 113 68 45 
Hospital contacts 94 80 14 
Intervention 1682 0 1682 
Fosinopril 1002 0 1002 
GP and pharmacist fees 295 0 295 
Screening* 385 0 385 
Total costs 
U ndiscou nted 1889 148 1741 
Discounted 1809 139 1670 
GP = general practitioner. 
*Costs of identifying 1person with albuminuria nthe baseline analysis. 
Baseline Cost-Effectiveness Analysis 
The higher CVE rate in the placebo group com- 
pared with the fosinopril group (6.5% vs 3.9%, re- 
spectively) translated into an estimated mean number 
of 0.28 discounted life-year lost per person not using 
fosinopril, compared with 0.18 year in those receiv- 
ing fosinopril. These figures were applied to the no- 
screening and screen-and-treat options, with the result 
that screen-and-treat was estimated to result in 0.10 LYG 
per person in the baseline analysis (slightly >1 month). 
In the baseline analysis, estimated mean cost- 
effectiveness was ~16,700 per LYG. Figure 2 shows 
the corresponding scatterplots for the 10,000 boot- 
strap replicates of net cost and effect in the cost- 
effectiveness plane, the estimated mean, and the 95% 
CI. Results are spread across the first and fourth 
quadrant of the cost-effectiveness plane. The estimat- 
ed cost-effectiveness was below the informal Dutch 
threshold of £20,000/LYG. 
Additionally, we determined the probability that 
the CER would be above or below various thresholds 
for maximum willingness to pay for 1 LYG (Figure 3). 
For 50% of the bootstrap replicates in the baseline 
analysis, estimated cost-effectiveness was below 
£16,500/LYG. For a maximum acceptable cost- 
effectiveness of£20,000, the probability of the screen- 
and-treat option being cost-effective was estimated at 
59% (Figure 3, Table V). 
Sensitivity Analysis 
In the sensitivity analysis, we analyzed the cost- 
effectiveness of limiting treatment to only those sub- 
jects with a UAE >30 or >50 mg/d (Figures 2 and 3; 
Table V). Estimated median CERs for those subjects 
were lower compared with the baseline analysis 
(£12,000, f~7000, and £16,500 for UAE >30, UAE >50, 
and baseline, respectively), and threshold probabilities 
increased to >90% for UAE >50 mg/d. Furthermore, 
the estimated median cost-effectiveness was lower for 
screening and treating subjects aged >50 years and 
>60 years compared with screening all subjects in the 
baseline analysis. 
DISCUSSION 
This study analyzed the cost-effectiveness of using fo- 
sinopril for the primary prevention of CVEs in subjects 
with albuminuria (UAE >15 mg/d) from the Dutch 
health care perspective. We estimated a mean CER 
for screening and subsequent fosinopril treatment 
(vs no screening) of £16,700/LYG. With a maximum ac- 
ceptable cost-effectiveness for The Netherlands of 
C20,000/LYG, our point estimate would be considered 
cost-effective. Analysis indicated an estimated 59% 
probability of the screen-and-treat s rategy being 
cost-effective. Although this percentage was not statis- 
tically significant for favorable cost-effectiveness, 
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Figure 2. Cost-effectiveness of screening for albuminuria nd subsequent fosinopril treatment compared with no 
screening (A) in all subjects with microalbuminuria (urinary albumin excretion [UAE] >15 rag/d) (cost- 
effectiveness ratio [CER] = £16,700/life-year gained [LYG]) and in sensitivity analyses in (B) subjects with 
UAE >30 mg/d (CER = £12,000/LYG) and (C) subjects with UAE >50 mg/d (CER = ~6900/LYG). Scatter- 
plots represent 10,000 replicates per analysis using the bootstrap method. Any cost-effectiveness plane con- 
tains net costs in euros (AC) on thex axis and LYG as effects (AE) on they axis. Dotted lines are 95% CIs, 
the dashed line is the estimated mean, and the solid line is the informal Dutch pharmacoeconomic thresh- 
old (C20,000/LYG). 
treatment appears to be worth consideration from a 
pharmacoeconomic perspective. It should be remem- 
bered that our study was designed to be hypothesis 
generating, and our results require further investiga- 
tion and confirmation. 
In sensitivity analyses, we investigated how the cost- 
effectiveness varied by subgroup. In particular, in sub- 
jects aged >50 years and >60 years, a relatively more 
favorable cost-effectiveness was estimated for a UAE 
cutoff of >15 mg/d. Also, limiting treatment to those 
subjects with a UAE >30 or >50 mg/d was associated 
with improved cost-effectiveness. 
Our study did not explicitly include assumptions 
about the specificity and sensitivity of the testing se- 
quence during screening (1 UAC measurement and 
two 24-hour UAE measurements), although testing 
performance is implicitly incorporated in the analysis. 
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Figure 3. Cost-effectiveness acceptability curves for screening For albuminuria and subsequent fosinopril treatment 
compared with no screening (A) in all subjects (baseline) and in sensitivity analyses in (B) subjects with 
urinary albumin excretion (UAE) >30 mg/d and (C) subjects with UAE >50 mg/d. Any curve represents the 
probability of the screen-and-treat approach being acceptable over a range of" cost-effectiveness thresh- 
olds for decision-makers' willingness to pay. The broken line on the x axis indicates the cost-effectiveness 
ratio of C20,000/life-year gained (informal Dutch pharmacoeconomic threshold), and the broken lines 
on they axis indicate 50% and 95% of the probability of acceptance. 
Table V. Median cost-effectiveness ratio (CER) and the probability oFacceptable cost-effectiveness 
given a threshold of C20,000 per life-year gained in the baseline and sensitivity analyses. 
Median CER, Probability of'Acceptable 
Analytic Group C Cost-Effectiveness 
All subjects (baseline) 16,500 0.59 
UAE >30 mg/d 12,000 0.72 
UAE >,SO mg/d 7000 0.91 
Subjects aged >50 y 13,600 0.63 
Subjects aged >60 y 6300 0.80 
UAE = urinary albumin excretion. 
morning urine sample is satisfactorily predictive of the 
UAE (specificity 85%). Some subjects with elevated 
albumin levels were missed (estimated sensitivity 85 %), 
but prescreening kept the burden and costs of popula- 
tion screening as low as possible. 44 If a better screen- 
ing procedure were to become available, the costs of 
identifying 1person with a UAE above a certain thresh- 
old would be lower and would probably result in a 
more favorable cost-effectiveness outcome. 
Only 1 study was found in the literature comp- 
arable to ours. This study investigated initial dipstick 
screening for proteinuria in a general population, with 
follow-up tests to confirm proteinuria and ini- 
tiate ACE-inhibitor treatment. 4s The study team's 
method of screening for proteinuria yielded fewer sub- 
jects than our method of screening for albuminuria, 
which explains their higher CERs (US $53,370- 
$282,800/QALY gained). In particular, because the 
prevalence of proteinuria was <1%, their approach re- 
quired screening of many individuals to identify 
I case. In data from the PREVEND study, 24,25 we found 
a prevalence of proteinuria of 1.1%, similar to that in 
the study by Boulware et al. However, the prevalence 
of a UAE >15 mg/d was 12.1%, 26 on which our cur- 
rent economic study is based. There were also dif- 
ferences between Boulware's and our approach in 
relation to health care systems and specific implemen- 
tations (GP-screening based vs population-screening 
based). 4s Of greatest importance, Boulware et al took 
into account only those savings that applied to the 
prevention of death from all causes and end-stage 
renal disease, whereas we focused on the effect of 
ACE inhibition in preventing CVEs. Inclusion of fo- 
sinopril treatment for subjects with overt proteinuria 
on screening instead of those with a UAE between 
15 and 300 mg/d would further improve the cost- 
effectiveness of screening, given the favorable cost- 
effectiveness of ACE-inhibitor therapy seen in subjects 
with proteinuria. 46 
Cost-effectiveness of ACE-inhibitor therapy in non- 
proteinuric populations has been studied. Bjorholt et 
a118 conducted a substudy of Swedish participants in 
the Heart Outcomes Prevention Evaluation trial to es- 
timate the cost-effectiveness of ramipril treatment for 
subjects with CVD or diabetes. Their findings indicat- 
ed net costs of £1940 to g5300/LYG. That estimate in- 
cluded treatment only; costs of screening were not 
considered. Based on our data, we estimated the cost- 
effectiveness of fosinopril treatment in subjects with 
albuminuria at C12,700/LYG (from the baseline 
analysis). 
The PREVEND IT study was directed at otherwise 
healthy people (no subjects with diabetes, high choles- 
terol levels, or high blood pressure); therefore, con- 
comitant drug use was expected to be relatively low 
and was not considered in the study. 
The strength of our study is that it combines 
population-based data on the prevalence of albumin- 
uria with outcomes of treatment in a subsection of that 
population. Also, the study was based on documented 
events occurring during follow-up of the PREVEND 
IT study, minimizing the number of assumptions re- 
quired to perform the entire analysis. The inherent 
limitation of our study is that it lacks data beyond the 
specified end point, such as nursing home care for 
stroke, rehabilitation after acute events, and potential 
rehospitalizations, with the corresponding costs (life- 
time costs of events were not taken into account in our 
analyses). Therefore, the cost-effectiveness may be even 
more favorable. Given the limited period of follow-up 
in the PREVEND IT study, lifetime health gains were 
modeled using Dutch data on remaining life expectan- 
cy and the Framingham life tables. 
A major drawback to the PREVEND IT study was 
that the apparent difference between lowering UAE 
and the incidence of CVEs was not statistically signifi- 
cant, possibly because of the limited number of sub- 
jects included. But, if the PREVEND IT study, which 
was performed on an intent-to-treat basis, were in- 
stead performed on a per-protocol basis, the relation- 
ship between UAE and CVEs would be statistically 
significant. The per-protocol analysis itself can be pro- 
vided on request. A larger sample size with longer 
follow-up (resulting in more events) might also have 
resulted in a statistically significant difference. Finally, 
this study was limited to a 1-time screening program; 
inclusion of subsequent screening(s) might result in less 
favorable cost-effectiveness. In general, cost-effectiveness 
analysis based on clinical trials has its limitations; in 
particular, the clinical trial does not reflect the real 
world, and the time frame is limited. 
Further work using our approach should involve 
the combination of a CVE and the progression of 
renal disease. For that purpose, aMarkov model could 
be developed with stages corresponding to albumin- 
uria levels, which would offer the opportunity to sim- 
ulate a periodic screening procedure in the general 
population. Such models have been developed with a 
focus on renal disease in subjects with diabetes, 21,47 
but they have not formally included CV risks. Also, 
such a Markov model would allow an investigation f
cost-effectiveness that included subsequent screening(s) 
and long-term CV and renal outcomes. 
The PREVEND and PREVEND IT studies were 
performed ina predominantly white population (>95% 
of subjects). This may theoretically imit the external 
validity of our analysis. However, in nonwhite sub- 
jects, the prevalence of microalbuminuria, as well as 
the incidence of CVD, has been shown to be substan- 
tially higher than in white subjects. 48-sl We believe 
that screening for albuminuria nd subsequent treat- 
ment with an ACE inhibitor may be more cost-effective 
in populations with larger proportions of black indi- 
viduals. In our study, we did not include the cost of 
complications of fosinopril treatment. Adverse vents 
(particularly cough) were reported by 3.5% (29) of 
subjects in PREVEND IT. 13 As these adverse vents 
were mild, they did not influence our cost-effectiveness 
estimate. The possibility of these complications leading 
to noncompliance was included in our study design. 
CONCLUSIONS 
This analysis from a Dutch health care perspective sug- 
gests the potential favorable cost-effectiveness of a 
screening program for albuminuria n the general pop- 
ulation. The estimated cost-effectiveness of approxi- 
mately £16,700/LYG for subjects with a UAE >15 mg/d 
was below the Dutch threshold for cost-effectiveness. 
Cost-effectiveness might be further improved by limit- 
ing screening to predefined subgroups (eg, by age, by 
limiting treatment to those with higher albuminuria 
levels). Further esearch isneeded to evaluate our find- 
ings in other settings using a longer time horizon, in- 
cluding periodically repeated screening and lifetime 
cost estimates. 
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